Document is current
Any future updates will be listed below
-
Authors
Pearce, Ian
Dinah, Christiana
Downey, Louise
Patwardhan, Ashish
Vardarinos, Athanasios
Williams, Gwyn
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
- License Information
-
More Information
Article History
Received: 3 November 2025
Accepted: 11 February 2026
First Online: 18 April 2026
Declarations
:
: Ian Pearce: Received consulting/lecture fees from AbbVie, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Novartis, and Roche/Genentech; Christiana Dinah: Received consulting fees from AbbVie, Apellis, Astellas, Boehringer Ingelheim, Eyepoint Pharmaceutical, Johnson and Johnson, Ocular Therapeutics, and Roche; reported speaker fees from Apellis, Bayer, Heidelberg Engineering, Roche, and Topcon; Louise Downey: Attendance at advisory boards support from Alimera, Allergan, Bayer, Novartis, Outlook Therapeutics, and Roche, research funding support from Alimera, Allergan, Bayer, Novartis, and Roche, travel support from Allergan, Bayer, Novartis, and Roche; Ashish Patwardhan: Attendance at advisory boards/received lecture fees/travel support from AbbVie, Alimera Sciences, Bayer, Novartis, and Roche; Athanasios Vardarinos: Attendance at advisory boards/received lecture fees/travel support from, Bayer, Biogen, Novartis and Roche; Gwyn Williams: No conflicts of interest declared.
: This study was conducted in accordance with the Declaration of Helsinki. The study was locally registered as a retrospective audit where patient identifiable data were omitted, therefore ethical approval was not required.
